Agoracom Blog Home

Posts Tagged ‘#smallcapstocks’

#Tech: Programmatic ads #Adtech are changing the media $GOOD.ca

Posted by AGORACOM-JC at 4:32 PM on Monday, September 24th, 2018
  • The US$550 billion ($758.6 billion) global advertising industry is undergoing a seismic transformation from what used to be a “spray and pray” approach
  • A brand advertiser selling BMWs or Rolexes would spray a lot of ads across the media spectrum and then pray that someone watching or looking at the ad might buy the car or luxury watch — to what is known as “programmatic advertising”, where the algorithm makes sure only the person who is looking to buy the BMW or Rolex gets to see the message

IF you are looking for the best-performing tech stock this year, don’t look at the usual suspects like ­Facebook, Amazon.com, ­Apple, Netflix and Google’s parent, Alphabet — the so-called FAANG names. Up over 211% this year, The Trade Desk sits at the crossroads of advertising and technology. In some ways, it is a competitor of Facebook, Google and Amazon. But more than that, this nemesis of old media — print newspapers, radio and TV — is helping transform the whole advertising landscape, including who sees ads, and where and when they see it.

The Trade Desk is a highly automated electronic marketplace where brand owners who want to place ads and publishers or website owners who are seeking ads make deals. Essentially, its algorithms help its agency clients purchase advertising programmatically, cutting out the human element. More­over, it does not operate the arbitrage model that many ad exchanges do, like buying ad inventory and selling it to clients for more. Instead, it simply charges its clients a fee based on total ad spend.

Two years ago, The Trade Desk launched its IPO at US$18 a share. It was, at the time, barely making money and investors seemed lukewarm about its prospects, betting that internet giants such as Google, Facebook or Snap would beat anything that the upstart could do. Fast forward to today, even as Facebook and Google have seen their own ad revenue growth start to flatline, The Trade Desk has beaten profit forecasts quarter after quarter for two years now. The stock is currently trading at US$147 a share, or up over eightfold since its IPO. The Trade Desk has actually tripled since early May, just before it reported spectacular first quarter results. Jefferies analyst Brent Thill expects it to report US$68 million ($97 million) in profits this year, up 35% over last year.

The big story since the Internet boom of 2000 has been the shrinking of old media, with ad-supported small-town newspapers, big-city magazines and terrestrial TV now a shadow of their former selves having lost advertising clients and revenues. The old model was based on eyeballs, reach and circulation, which helped media owners leverage on advertising. The new media model is subscription-based, and whatever little advertising garnered is just the cream on top. Brand owners now have all the data they want and are able to precisely target their ads to just the audience they want to reach rather than the pie in the sky promised by old media firms.

Seismic shift

The US$550 billion ($758.6 billion) global advertising industry is undergoing a seismic transformation from what used to be a “spray and pray” approach — where a brand advertiser selling BMWs or Rolexes would spray a lot of ads across the media spectrum and then pray that someone, somewhere watching or looking at the ad might buy the car or luxury watch — to what is known as “programmatic advertising”, where the algorithm makes sure only the person who is looking to buy the BMW or Rolex gets to see the message.

If I regularly search for BMW dealers in my city or recently googled a price comparison for Rolex, the algorithm would push relevant ads to me. If, however, I have been searching online mainly for a second-hand Toyota, the advertiser would be wasting time, money and effort trying to sell me a BMW even though I might be living in some fancy upscale neighbourhood. Programmatic advertising basically helps cuts through the chase, avoids wastage and connects sellers with real buyers at a fraction of the cost of “spray and pray” advertising.

Ads are more targeted, though we feel we are no longer inundated by them. There are fewer newspapers and magazines. Those that have survived are thinner. There are fewer ads on TV and radio, and subscription channels such as Netflix have no advertising, although Amazon is reportedly planning an ad-supported video service to complement its ad-free Amazon Prime streaming movies and videos.

Yet total global ad spending is still growing. Research firm PQ Media estimates that global ad and marketing spending will increase 4.6% in 2019 following 5.5% growth this year, the fastest since the 2008 financial crisis. Traditional ad spending is expected to rise just 0.8% compared with an expected increase of 10.7% in digital spending ad spending. Magna Global forecasts digital ad spending will grow to US$250 billion this year, or 45% of total global ad spend.

The likes of Google and Facebook are still growing their total ad revenues at a 25% annual clip. By next year, half of all digital ad spending could be programmatic, Magna Global notes in a recent report. Brand safety concerns and anxiety over recent data scandals are not having any discernible impact on digital advertising growth, the report says. Programmatic ad spend is forecast to grow to over 57% of digital display ad transactions by 2020, from just over 40% currently.

Rise of the ‘Math Men’

Advertising used to be dominated by crazy, creative types symbolised by the fictional Don Draper from the award-winning period American TV serial Mad Men, set in the late Sixties and Seventies, which ran for eight years until mid-2015. Back then, advertising agencies were conglomerates of sorts. They produced TV commercial jingles, display print ads and also picked the media where the ads were placed. With the rise of global media-buying agencies such as Media­Com, Mindshare and Zenith, the media men got into the driving seat after the creative part of the agencies split from the media buying part two decades ago. Now, increasingly it is the “Math Men”, coders or software engineers who empower the algorithms that make most of the major decisions in the ad agencies — like how much money needs to be allocated to what media and how a brand owner can precisely target the exact demographics they want to reach.

In his recent book, Frenemies, The Epic Disruption of the Ad Business (and Everything Else), veteran media watcher Ken Auletta notes that the rise of programmatic advertising is helping coders “transform what was an instinctual art into a science”.

To be sure, the advertising industry has long used technology and data to carefully target ads. But it was not until the arrival of Google and Facebook, which not only collected a ton of very personalised data but were able to slice and dice it to maximum effect, that the advertising industry moved from being a relationship business to one that is data driven. Nowadays, it does not matter what the circulation of your newspaper is, how many households your TV station reaches or how many clicks a clickbait website gets, the algorithm already has it all figured out who gets to see the ads. While there was once an information arbitrage that media owners could presumably milk to their advantage, now there is none.

So, what exactly is programmatic advertising? Think of it as the automation of online advertising to allow the buying and selling of ad inventory electronically. “Programmatic ad buying is not just efficient, it also enables more sophisticated and carefully targeted ad campaigns,” notes Mark Mahaney, internet analyst for RBC Capital in San Francisco. Once confined to mostly display ad inventory, programmatic advertising has grown to include mobile, audio and video inventory as well. Moreover, programmatic ads once the domain of developed markets like the US and Europe are now driving ad spending in Asia, including Japan, China, Korea, Southeast Asia and India.

Here is how most of the ads we see online are delivered these days: Let’s say you surf a news website. As the site’s content starts loading on your screen, the publisher, through the use of cookies it has placed inside your device, finds that it has a lot of information stored about you. The publisher then sends the information to the ad server asking it whether there is an ad campaign available targeting someone like you. If there is none, the server seeks to match the impression programmatically, requesting responses from selected traders, ad networks or supply-side ad platforms. If the impression is not cleared, the request is sent to an open ad exchange which, in turn, sends a bid request containing information about your browser and the website you are surfing as well as the ad type to multiple bidders including traders, ad networks and demand-side platforms.

Each bidder processes the bid request, overlays it with additional user data as well as marketers’ targeting and budget rules. Each bidder’s algorithm evaluates the request, selects the ad and sends it along with the optimal bid price to the ad exchange, which selects the winning bid. The ad exchange sends the winning ads’ URL and price to the publisher’s ad server, which tells your browser which ad to show. The whole process takes up to 200 milliseconds.

Programmatic campaigns are particularly popular among finance, technology and automotive brands. Google, ­Apple, Samsung Electronics, ­Proctor & Gamble, L’Oreal, Unilever, Amazon and auto insurer Geico were among the top programmatic advertisers last year, but banks such as JPMorgan, and telco giants like ­Verizon and General Motors are pouring more of their ad dollars into programmatic advertising.

Targeted advertising

Ad tech firms like The Trade Desk are helping to enhance targeted advertising as Google, Facebook and Amazon use their massive data sets to help advertisers focus on customers with more detail. Algorithms allow ad buyers to set consumer-targeting parameters like, say, women between 25 and 35 who buy at least two pairs of shoes every three months, matching brand advertisers’ demand to a publisher’s supply at instantaneous market-clearing prices.

I recently bought a leather office chair online. Since then, I have been in­undated with ads from online furniture retailers such as Wayfair, Birch Lane as well as Amazon before I watch Youtube videos, as well as ads from home decoration firms.

Last week, ads from companies selling wallpaper suddenly started to appear each time I logged in to the New York Times website. Combining data sets with correlated behaviours and trackable purchase outcomes is what makes Google, Facebook and Amazon so important in the advertising world, and an increasing disintermediation threat to the ad industry because data analy­tics was once a key competitive advantage of media buying agencies.

If you want to understand how the global advertising industry is being transformed, look no further than WPP, the world’s largest advertising holding  firm, which earlier this year fired its long-time CEO Sir Martin Sorrell. Its stock has plunged 39% from its peak 18 months ago because investors believe ad agencies are no longer powerful middle men as they once were. Large clients are increasingly in-sourcing some of the work they used to farm out to advertising groups because they now have a lot of data themselves and are loathe to have an outside firm collect their data, slice and dice it and tell them what they need to do.

Investors are betting that with their falling margins and diminishing intermediary role, ad giants such as WPP deserve to be de-rated. Last week, WPP named Mark Read to replace Sorrell, who at 73 has gone on to set up his own tech-focused ad group, and remake the firm into a leaner, meaner outfit that can thrive in a world where advertising is increasingly programmatic.

Source: http://www.theedgemarkets.com/article/tech-programmatic-ads-are-changing-media

CLIENT FEATURE: Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 10:28 AM on Monday, September 24th, 2018

WHY BOUGAINVILLE?

  • Converting irrigated farmland to greenhouse-equipped farmland
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure as a landlord for licensed marijuana growers
  • First 10,000 square feet (of 30,000 sqf) greenhouse space has been completed
  • Ready for occupancy
  • Room for expansion
  • JV Agreement with Marijuana Company of America (MCOA:OTC)
  • MCOA investment of $1M

Early estimates show a greenhouse can produce twice the amount of product and at least less than 50% of the cost compared to warehouse production.

FULL DISCLOSURE: Bougainville Ventures is an advertising client of AGORA Internet Relations Corp.

Tetra Bio-Pharma $TBP.ca Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:00 AM on Monday, September 24th, 2018

Logo tetrabiopharma rgb web

  • Made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market
  • Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised

ORLEANS, Ontario, Sept. 24, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market.

Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised.  This was the first clinical trial of its kind in evaluating the safety and efficacy of different doses and ratios of cannabis oils versus placebo.  The study included a dose titration phase (gradually bringing patients to the required dose) allowing us to better understand the side effect profile of the oils as well as the development of tolerance to these effects.  Thus far, no other company in the medical cannabis space has undertaken such an exhaustive study to understand the therapeutic benefits and side effects of a cannabis oil-based capsule.

Dr. Chamberland, interim CEO and CSO added, “We continue to deliver on our business model that provides for evidence-based research to support the usage of cannabis-derived products and provide the medical community with the data they have been demanding from this sector. The trial has already provided unique valuable clinical data on both safe and efficacious dose levels of CBD and THC-CBD oils.  This data will allow Tetra to advance to the next phase of product development wherein the company is developing products for its commercial partner Genacol Corporation Canada, as well as food supplements for the retail market and finally, our capsules that we intend to use in the treatment of chronic and cancer related pain.  Tetra has already established itself as a trailblazer in the natural health product segment with the announcement of our intention to launch a Hemp Energy Drink and we intend to build on that momentum.”

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP005, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

 

INTERVIEW: American Creek #AMK.ca Discusses Potential Quantity and Grade of Gold Mineralization (1.8 – 1.9 Million Ounces @ 1.12 – 1.35 G/t) at the Treaty Creek $SEA $SA $SKE.ca $TUD.ca $PVG $MRO.ca

Posted by AGORACOM-JC at 8:36 AM on Monday, September 24th, 2018

INTERVIEW: CFN Interviews Ryan Brown about $NBUD.ca Strategy $TLRY

Posted by AGORACOM-JC at 3:04 PM on Friday, September 21st, 2018

North Bud Farms Inc (C.NBUD) CEO Ryan Brown met with CannabisFN Media to lay out and explain the company’s strategic and future direction as the industry moves closer into Legalization 2.0.

The company is focusing on a sustainable production and procurement of cannabinoids while pursuing a license under the Access To Cannabis for Medical Purpose Regulations (ACMPR).

AGORACOM Welcomes North Bud Farms Inc. $NBUD.ca Focusing On Sustainable Low Cost, High Quality Cannabinoid Production

Posted by AGORACOM-JC at 8:43 AM on Friday, September 21st, 2018

Northbud large

WHY NORTH BUD FARMS INC?

  • Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening in 2019
    As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
  • Infused products sector has become the highest margin segment of the industry
  • Positioned to be a raw input producer for this space
  • Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products

THE OPPORTUNITY

  • Acquired late stage ACMPR applicant GrowPros
    MMP from Tetra Bio-Pharma (TSXV: TBP)
  • GrowPros MMP application was submitted in November 2014 and is currently in the ‘Confirmation of Readiness’ stage.
  • Phase 1 is located on 95 acres of agricultural farmland in Low, Québec.
  • Option exists to acquire more land if needed
  • Facility will focus on GMP (higher production grade) pharma-grade cultivation and food-grade extracted inputs

LOCATION

SITE DETAILS: LOW COST INFRASTRUCTURE

POSITIONED FOR LEGALIZATION 2.0

  • First mover advantage often becomes first-mover disadvantage
    Examples: AOL, Netscape, Yahoo, BlackBerry
  • Second mover advantage: clearer picture of market and competition
    Examples: Google, Facebook, Amazon, Apple, NORTHBUD

STRATEGIC VERTICALS

Pharma Development

  • North Bud will focus on GMP standardized production to be used by our pharma commercialization partners i.e. Tetra Bio-Pharma We will focus on securing unique strains containing high amounts of specific cannabinoids not typically found in recreational cannabis.

Food Grade Inputs

    • Using our licensed encapsulation technology we will
      engage existing food and beverage companies looking
      to develop product lines containing cannabis.

ReadyUp raises $2 million to manage #Esports teams and help players improve $GMBL $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca

Posted by AGORACOM-JC at 1:29 PM on Thursday, September 20th, 2018
Dean Takahashi@deantak September 20, 2018 5:30 AM
  • ReadyUp, a platform for player connection and team management for gaming and esports, has raised $2 million in funding from game-savvy investors.
  • The combined company has 11 people in San Francisco, and they will focus on a few different missions related to esports, said Alemania, in an interview with GamesBeat.
Every business leader needs to truly understand how AI is a gamechanger. Join other senior execs at VB Summit, Oct 22 & 23, 2018 in Mill Valley, CA. Grab your ticket now at 30% off.

ReadyUp, a platform for player connection and team management for gaming and esports, has raised $2 million in funding from game-savvy investors.

Last month, ReadyUp acquired Ready Up Live, a gaming community site that was doing some of the same things as ReadyUp. That deal brought together a number of game veterans and celebrities, including Roderick Alemania, CEO of ReadyUp, and famous pro gamer and ReadyUp cofounder Johnathan “Fatal1ty” Wendel, and Ready Up Live founder Dan “Greenskull” Hammill, a celebrity gamer who has 262,000 subscribers on YouTube.

The combined company has 11 people in San Francisco, and they will focus on a few different missions related to esports, said Alemania, in an interview with GamesBeat.

“Our mission is to be the epicenter of the esports community, so that people can find people they actually want to play with,” he said. “The idea across the pillars of that mission is to meet, compete, and get better. And we have a really strong team of people who have been in the game business for decades.”

In terms of meeting, the company wants to create a matchmaking service where esports players can find people they want to play with, rather than just play pickup multiplayer games all of the time with strangers.

In terms of “compete,” the company will also help esports players find teams, and help teams find esports players, or even help players find others so they can form esports teams. Alemania compared this to the application TeamSnap, which helps parents deal with changes and details for their children’s sports team. In the case of players, this solution would help teams figure out who is playing in a particular match or is not available. This will enable team managers to focus on team and player development, rather than logistics.

And in terms of “get better,” ReadyUp will create a marketplace for services that parties can offer, such as coaching services for Fortnite. And it will provide other services that enable players to get better and play with their friends.

“We called our friends at the major publishers and asked if they were doing this, and they all said no,” Alemania said. “We saw we could fill a need in the market. It can address a massive pain point for teams.”

The cofounders like Wendell and Hammill get asked to provide coaching, paid or not, all of the time. But this marketplace would provide an organized way to scale up such services to a much larger level, Alemania said.

San Francisco-based ReadyUp was founded in 2017 to benefit amateur and professional gamers, teams, and gaming clans. The platform is set to launch later this year, with other services coming next year. Investors include Boost VC, which led the round, as well as Fenwick & West, Smith & Crown, and other individual investors from across gaming, sports, esports, blockchain and other sectors.

“ReadyUp will change competitive video gaming and esports on a fundamental level,” said Jay Cohen, former president of Wargaming America, in a statement. “By providing an on-ramp for gamer connection, player development, and competition, ReadyUp lets every gamer, team, and the esports industry as a whole to reach their full potential. The ReadyUp platform will not only accelerate the path to revenue for players, teams, and partners, it is the spark for the wildfire that is waiting to happen.”

Lead investor Boost VC is a blockchain and virtual reality accelerator with a portfolio of more than 200 companies including Coinbase.

“ReadyUp has assembled an awesome team of accomplished, experienced and well connected executives.” said Adam Draper, founder and managing partner, in a statement. “Their process of product validation and design coupled with a feedback loop from gamers puts ReadyUp in a great position to build a successful company that will capitalize on the $900 million esports industry.”

Source: https://venturebeat.com/2018/09/20/readyup-esports-team-management-firm-raises-2-million/

North Bud Farms $NBUD.ca Closes $944,500 Private Placement $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:40 AM on Thursday, September 20th, 2018

Northbud large

  • Announced the closing of a non-brokered private placement offering consisting of 3,778,000 units, at a price of $0.25 per Unit, for gross proceeds of $944,500.
  • Each Unit is comprised of one Common Share and one-half (1/2) of a Common Share purchase warrant, with each whole warrant entitling the holder hereof to acquire one additional Common Share at a price of $0.40 per Common Share until September 20, 2020

TORONTO, Sept. 20, 2018 – North Bud Farms Inc. (CSE: NBUD) (the “Corporation“), is pleased to announce the closing of a non-brokered private placement offering (the “Private Placement“) consisting of 3,778,000 units (“Units“), at a price of $0.25 per Unit, for gross proceeds of $944,500. Each Unit is comprised of one Common Share and one-half (1/2) of a Common Share purchase warrant, with each whole warrant entitling the holder hereof to acquire one additional Common Share at a price of $0.40 per Common Share until September 20, 2020.  No fees or commissions were paid in connection with the Private Placement.  The terms of the Private Placement are the same as the Corporation’s previously-completed private placement (July 25, 2018, as disclosed in the Corporation’s prospectus dated August 21, 2018).

Mr. Andre Audet, the Chairman of the Corporation, participated in the Private Placement by subscribing for 200,000 Units (the “Insider’s Participation“).  The Insider’s Participation is exempt from the formal valuation and minority shareholder approval requirements provided under Multilateral Instrument 61-101 Protection of Minority Holders in Special Transactions (“MI 61-101“) in accordance with sections 5.5(a) and 5.7(a) of MI 61-101. The exemption is based on the fact that neither the fair market value of the Insider’s Participation nor the consideration paid by such insider exceeds 25% of the Corporation’s market capitalization. The Corporation did not file a material change report at least 21 days prior to the completion of the Private Placement since the Insider’s Participation was not determined at that moment.

The Corporation intends to use the proceeds of the Private Placement to continue to advance the license application of GrowPros MMP Inc. under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and for general working capital purposes.

The securities acquired by the subscribers are subject to a hold period of four months plus one day from the closing date, ending on January 21, 2019, except as permitted by applicable securities legislation.

About North Bud Farms Inc.

North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farm’s final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tetra Bio-Pharma $TBP.ca Announces Significant Progress on Storz & Bickel Co-Development in Treating #Fibromyalgia $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:09 AM on Thursday, September 20th, 2018

Logo tetrabiopharma rgb web

  • Made significant progress in its co-development partnership with Storz & Bickel
  • The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada

ORLEANS, Ontario, Sept. 20, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its co-development partnership with Storz & Bickel.  The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada.  In addition, Tetra Bio-Pharma expects to complete the identification of every compound in the PPP001 vapor generated by the Mighty Medic vaporizer later this month.  Tetra intends on initiating a Phase 1 clinical study in healthy volunteers to determine the safety and pharmacokinetics of its vaporized PPP001 drug later this year.

This clinical data and vapor compound identification will allow Tetra to bridge to its existing and future clinical data of the Phase 3.  The bridge will provide a significantly reduced time to market and reduced development cost for the commercialization of PPP001 as a treatment for fibromyalgia.

“The Independent Ethics Board approval represents a major step forward prior to obtaining approval from Health Canada and the clinical study will allow Tetra to accelerate bringing PPP001 for fibromyalgia patients,” stated Dr. Guy Chamberland, Ph.D., Interim CEO and CSO at Tetra Bio-Pharma.  “We are very confident in Tetra’s strategy to become a global leader in the development of cannabinoid derived prescription and natural health products.”

About Storz & Bickel
STORZ & BICKEL built the first factory in the world for the manufacture of medical herbal vaporizers in Tuttlingen, Germany, a town with almost 500 medical device manufacturers. Tuttlingen is reputed to be the center of medical technology, where the first factory to produce surgical instruments was established more than 150 years ago.

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]

Stephanie Engel
416-425-9143 ext. 209
[email protected]

CLIENT FEATURE: Star Navigation $SNA.ca Real-Time Flight Tracking and Monitoring Technology

Posted by AGORACOM-JC at 3:25 PM on Wednesday, September 19th, 2018

STAR-A.D.S.®

  • On-board real-time monitoring and data analysis system that provides a “virtual window into an aircraft”
  • As cost-effective air to ground communication system that automatically and securely transmits flight data and incident alerts.
  • Continuously monitors selected avionics systems on the aircraft from power-on to power-off, instantly analyzes the data, and transmits selected data and any incident alerts, via satellite to the operator.
  • Acts as an early warning system, detecting the earliest signs of potential problems
  • Performs these functions in “real-time” providing essential safety monitoring to the benefit of passengers, aircraft personnel, and ground crew
  • Applications include: Commercial Airlines, Helicopters, Business Aircraft, Assist Search and Rescue by providing last transmitted location
  • Recent applications: Emergency Medical Services (airborne and ground vehicles), Land vehicles

CHECK OUT RECENT INTERVIEW

FULL DISCLOSURE: Star Navigation Systems Group Ltd. is an advertising client of AGORA Internet Relations Corp.